Brief: Bionomics Receives FDA Clearance Of IND For Evaluation Of BNC210 In Phase 2 Social Anxiety Disorder Prevail Study
31/10/2021 23:13
Nov 1 (Reuters) - Bionomics Ltd BNO.AX :
* RECEIVES FDA CLEARANCE OF IND FOR EVALUATION OF BNC210 IN
A
PHASE 2 SOCIAL ANXIETY DISORDER PREVAIL STUDY
Source text for Eikon: ID:nASX50fDqk
Further company coverage: BNO.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bionomics
See all newsBrief: Bionomics Announces Intention To Delist From The Australian Securities Exchange (ASX)
Brief: Bionomics Announces Its Intention To De-List From Australian Securities Exchange
Australia's Bionomics plunges to record low after co announces ASX delisting
Brief: Bionomics Ltd Seeks Trading Halt
Brief: Bionomics Says Alan Fisher Appointed Chair Of Board Of Directors